The exploratory study to evaluate the association between efficacy of bevacizumab combination therapy and pretreatment plasma vascular endothelial growth factor-D levels in metastatic colorectal cancer (GI-SCREEN-CRC-Ukit additional study 01)

The exploratory study to evaluate the association between efficacy of bevacizumab combination therapy and pretreatment plasma vascular endothelial growth factor-D levels in metastatic colorectal cancer (GI-SCREEN-CRC-Ukit additional study 01) - GI-SCREEN-CRC-Ukit additional study 01

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043800

Enrollment

300

Registered

2021-04-01

Start date

2021-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients enrolled in the GI-SCREEN CRC-Ukit study (UMIN000028616) who have consented to the secondary use of plasma samples and have not withdrawn their consent. 2) Patients are enrolled in (1), (2), and (5) of the following five cohorts (1) Chemotherapy plus bevacizumab (first line) (2) Chemotherapy plus anti-EGFR antibody (first line) (3) FOLFIRI plus ramucirumab (second line) (4) FOLFIRI plus aflibercept (second line) (5) Chemotherapy plus bevacizumab (second line) 3) There are residual samples available for VEGF-D testing.

Exclusion criteria

Exclusion criteria: 1) Unsuitable for the study according to the opinion of the investigators

Design outcomes

Primary

Measure	Time frame
To evaluate the association between plasma VEGF-D levels and the efficacy of bevacizumab combination therapy in patients with colorectal cancer.	—

Countries

Japan

Contacts

Public ContactHiroya Taniguchi

National Cancer Center Hospital East Department of Gastroenterology and Gastrointestinal Oncology

hirtanig@east.ncc.go.jp04-7133-1111

Outcome results